- Steve Berger Apr 17, 2018 at 04:36: PM
Seems like most who try it never refill it. Horrible retention numbers. Makes me believe the product isn’t as great as the shills on message boards/twitter make it out to be.
-
Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page
You would think that inhaling vs poking needles in hand would be better.
But it’s overpriced, no formulary coverage, and doctors are confused by the dose.
Outside of those minor points, it’s stellar.
But it’s overpriced, no formulary coverage, and doctors are confused by the dose.
Outside of those minor points, it’s stellar.
And don't forget...the leadership is clueless!
Why are you agreeing with the thread you started? lol. I can't wait until Nassi fires you for your lousy numbers Steve "Cheese" Berger
- BetterForIt Jul 12, 2018 at 01:44: PM
The product works. I have 2 friends who swear by it. I see it in action every week. The reviews (most) are sincere. There is no formal afrezza army. this company is not that sophisticated. Agree with whats above tho- management issues (egos + hiring buddies), dosing confusion, field force not supported and no funding for marketing.
Considering how very few people use (or have ever tried) Afrezza, it is remarkable that you actually know TWO of them.
No. Not it's not great. It's ineffective even in a small niche market. The business would close if it was a private concern, but insiders milking this pig off back of shareholder cult members. Inhaled insulin is dangerous and unwanted. PFE and SNY tried and failed. This is more of a failure.
...Says some who obviously doesn’t know much about diabetes. Honestly, you’d have to be an idiot to purchase this molecule and base the success of a company on it. Type II diabetics are on injectables like GLP-1 agonists and long acting insulin LONNNGG before adding fast acting insulin. Type 1 diabetics are typically diagnosed young and have been injecting for many years by the time they can use Afrezza since it’s approved for ADULT Type 1’s. Sorry, as a provider I’d never prescribe Afrezza. Why would I switch a well controlled patient to a product that increase the chance of lung cancer (duh...introducing a growth hormone-like molecule to non-native cells plus study subjects were non-smokers!) and potentially decrease pulmonary function when they can simply continue with their 100 year old tried and true insulin. Not enough benefits to take the risk in my patients.
And to set the record straight on inhaled insulin’s...Pfizer withdrew Exubera from the market, and in 2017 Sanofi withdrew from a marketing agreement with MannKind for Afrezza; both removals were due to poor sales volume. Soooo...unfortunately people (leadership) can act irrationally and desperately when their plane is taking a nose dive. It’s not surprising sales force have been fired. I’m sure it’s ALLLL their fault (not!) that providers are being responsible and not prescribing this crash and burn product instead of leadership accepting defeat.
...Says some who obviously doesn’t know much about diabetes. Honestly, you’d have to be an idiot to purchase this molecule and base the success of a company on it. Type II diabetics are on injectables like GLP-1 agonists and long acting insulin LONNNGG before adding fast acting insulin. Type 1 diabetics are typically diagnosed young and have been injecting for many years by the time they can use Afrezza since it’s approved for ADULT Type 1’s. Sorry, as a provider I’d never prescribe Afrezza. Why would I switch a well controlled patient to a product that increase the chance of lung cancer (duh...introducing a growth hormone-like molecule to non-native cells plus study subjects were non-smokers!) and potentially decrease pulmonary function when they can simply continue with their 100 year old tried and true insulin. Not enough benefits to take the risk in my patients.
And to set the record straight on inhaled insulin’s...Pfizer withdrew Exubera from the market, and in 2017 Sanofi withdrew from a marketing agreement with MannKind for Afrezza; both removals were due to poor sales volume. Soooo...unfortunately people (leadership) can act irrationally and desperately when their plane is taking a nose dive. It’s not surprising sales force have been fired. I’m sure it’s ALLLL their fault (not!) that providers are being responsible and not prescribing this crash and burn product instead of leadership accepting defeat.
...Says some who obviously doesn’t know much about diabetes. Honestly, you’d have to be an idiot to purchase this molecule and base the success of a company on it. Type II diabetics are on injectables like GLP-1 agonists and long acting insulin LONNNGG before adding fast acting insulin. Type 1 diabetics are typically diagnosed young and have been injecting for many years by the time they can use Afrezza since it’s approved for ADULT Type 1’s. Sorry, as a provider I’d never prescribe Afrezza. Why would I switch a well controlled patient to a product that increase the chance of lung cancer (duh...introducing a growth hormone-like molecule to non-native cells plus study subjects were non-smokers!) and potentially decrease pulmonary function when they can simply continue with their 100 year old tried and true insulin. Not enough benefits to take the risk in my patients.
And to set the record straight on inhaled insulin’s...Pfizer withdrew Exubera from the market, and in 2017 Sanofi withdrew from a marketing agreement with MannKind for Afrezza; both removals were due to poor sales volume. Soooo...unfortunately people (leadership) can act irrationally and desperately when their plane is taking a nose dive. It’s not surprising sales force have been fired. I’m sure it’s ALLLL their fault (not!) that providers are being responsible and not prescribing this crash and burn product instead of leadership accepting defeat.
...Says some who obviously doesn’t know much about diabetes. Honestly, you’d have to be an idiot to purchase this molecule and base the success of a company on it. Type II diabetics are on injectables like GLP-1 agonists and long acting insulin LONNNGG before adding fast acting insulin. Type 1 diabetics are typically diagnosed young and have been injecting for many years by the time they can use Afrezza since it’s approved for ADULT Type 1’s. Sorry, as a provider I’d never prescribe Afrezza. Why would I switch a well controlled patient to a product that increase the chance of lung cancer (duh...introducing a growth hormone-like molecule to non-native cells plus study subjects were non-smokers!) and potentially decrease pulmonary function when they can simply continue with their 100 year old tried and true insulin. Not enough benefits to take the risk in my patients.
And to set the record straight on inhaled insulin’s...Pfizer withdrew Exubera from the market, and in 2017 Sanofi withdrew from a marketing agreement with MannKind for Afrezza; both removals were due to poor sales volume. Soooo...unfortunately people (leadership) can act irrationally and desperately when their plane is taking a nose dive. It’s not surprising sales force have been fired. I’m sure it’s ALLLL their fault (not!) that providers are being responsible and not prescribing this crash and burn product instead of leadership accepting defeat.